InVitro International Engages Askew Kabala and Company, Inc. to Further Advance Its Corporate Growth Plan
Rhea-AI Summary
InVitro International (OTCQB: IVRO) has announced the engagement of Askew Kabala and Company, Inc. (AKC) as a consultant to support and advance the company's corporate growth plan. AKC will provide business advising, investment banking, management, and strategy services to IVRO. The consulting firm will offer executive and organizational support, including strategy refinement, planning, and operational review.
IVRO CEO W. Richard Ulmer expressed enthusiasm about the partnership, stating that the company is adapting well to post-Covid-19 and inflationary times by adding guidance from experienced professionals. The engagement with AKC comes in the final month of IVRO's Fiscal 2024 Year, signaling a strategic move to enhance the company's growth trajectory.
Positive
- Engagement of experienced consulting firm Askew Kabala and Company, Inc. to support corporate growth plan
- Addition of business advising, investment banking, management, and strategy services
- Potential for improved strategy refinement, planning, and operational review
Negative
- None.
News Market Reaction – IVRO
On the day this news was published, IVRO gained 66.67%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Placentia, California--(Newsfile Corp. - September 3, 2024) - Today InVitro International (OTCQB: IVRO) is pleased to announce that it has engaged Askew Kabala and Company, Inc. as consultant to the company. AKC will act in a business advising, investment banking, management and strategy role to support and advance IVRO's previously announced corporate growth plan. AKC will provide executive and organizational support, including strategy refinement, planning and operational review & more where needed & appropriate.
IVRO CEO, W. Richard Ulmer, said: "InVitro believes it is adapting well to post-Covid '19 & inflationary times by adding guidance from experienced minds with an outstanding past performance record. We are delighted to have met and now partnered with Ron Askew and his team in this final month of our Fiscal '24 Year."
About InVitro International, Inc.
InVitro International, Inc., headquartered in Placentia, California, was founded in 1985 and is a customer and technology-driven provider of non-animal testing methods. The Company's testing technologies are designed to produce data regarding corrosivity and ocular/dermal irritation, which correlate with animal and human test results. IVRO's technology is commercialized globally through test kits and partner laboratory services.
This release may contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by forward looking statements. These risks and uncertainties include but are not limited to acceptance of the Company's technology by customers or regulatory agencies, changes in market conditions and other competitive factors. The forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update such statements.
Company Contact:
W. Richard Ulmer
Chief Executive Officer and Chairman
(800)246-8487
invitro@invitrointl.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/221834
FAQ
What consulting firm has InVitro International (IVRO) engaged to support its growth plan?
What services will Askew Kabala and Company provide to InVitro International (IVRO)?
When did InVitro International (IVRO) announce its engagement with Askew Kabala and Company?
How does InVitro International (IVRO) view its adaptation to post-Covid-19 and inflationary times?
